B. Riley Has Positive Estimate for Vaxart FY2024 Earnings

Vaxart, Inc. (NASDAQ:VXRT) – B. Riley increased their FY2024 earnings per share (EPS) estimates for shares of Vaxart in a report issued on Monday, November 18th. B. Riley analyst M. Mamtani now expects that the biotechnology company will post earnings of ($0.40) per share for the year, up from their previous estimate of ($0.54). The consensus estimate for Vaxart’s current full-year earnings is ($0.43) per share. B. Riley also issued estimates for Vaxart’s Q4 2024 earnings at ($0.11) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.27) EPS and FY2026 earnings at ($0.28) EPS.

Separately, Oppenheimer started coverage on Vaxart in a report on Thursday, August 15th. They set an “outperform” rating and a $4.00 target price on the stock.

Vaxart Price Performance

Shares of Vaxart stock opened at $0.60 on Thursday. The stock has a market cap of $106.33 million, a P/E ratio of -1.46 and a beta of 0.70. The stock’s 50 day simple moving average is $0.78 and its 200-day simple moving average is $0.77. Vaxart has a 1-year low of $0.52 and a 1-year high of $1.54.

Institutional Trading of Vaxart

A number of large investors have recently modified their holdings of the stock. Mesirow Financial Investment Management Inc. grew its stake in shares of Vaxart by 100.0% during the third quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 20,000 shares in the last quarter. Tidal Investments LLC acquired a new position in Vaxart in the first quarter valued at $56,000. Sequoia Financial Advisors LLC acquired a new position in Vaxart in the second quarter valued at $65,000. XTX Topco Ltd boosted its stake in Vaxart by 869.3% in the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock valued at $116,000 after acquiring an additional 122,387 shares in the last quarter. Finally, Monaco Asset Management SAM acquired a new position in Vaxart in the second quarter valued at $402,000. Hedge funds and other institutional investors own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.